Show simple item record

dc.contributor.authorHalliwell, S
dc.contributor.authorWarn, P
dc.contributor.authorSattar, A
dc.contributor.authorDerrick, JP
dc.contributor.authorUpton, Mathew
dc.date.accessioned2017-03-06T14:49:47Z
dc.date.accessioned2017-03-06T14:50:07Z
dc.date.available2017-03-06T14:49:47Z
dc.date.available2017-03-06T14:50:07Z
dc.date.issued2016-12-13
dc.identifier.issn0305-7453
dc.identifier.issn1460-2091
dc.identifier.urihttp://hdl.handle.net/10026.1/8589
dc.description.abstract

OBJECTIVES: To investigate the efficacy of a potent novel antimicrobial protein of mass 6 kDa, epidermicin NI01, for eradicating the nasal burden of MRSA in a cotton rat ( Sigmodon hispidus ) model. METHODS: MRSA strain ATCC 43300 was used to establish a robust colonization of cotton rat nares. This model was used to evaluate the efficacy of topical 0.04% and 0.2% epidermicin NI01, administered twice daily for 3 days consecutively, and topical 0.8% epidermicin NI01 administered once, for reducing nasal MRSA burden. Control groups remained untreated or were administered vehicle only (0.5% hydroxypropylmethylcellulose) or 2% mupirocin twice daily for 3 days. The experiment was terminated at day 5 and MRSA quantitative counts were determined. Tissues recovered from animals treated with 0.2% epidermicin twice daily for 3 days were examined for histological changes. RESULTS: Mupirocin treatment resulted in a reduction in burden of log 10 (log R) of 2.59 cfu/nares compared with vehicle ( P  < 0.0001). Epidermicin NI01 administered once at 0.8% showed excellent efficacy, resulting in a log R of 2.10 cfu/nares ( P  = 0.0004), which was equivalent to mupirocin. Epidermicin NI01 administered at 0.2% or 0.04% twice daily for 3 days did not have a significant impact on the tissue burden recovered from the nares. Mild to marked histological abnormalities were noted, but these were determined to be reversible. CONCLUSION: A single dose of topical epidermicin NI01 was as effective as mupirocin administered twice daily for 3 days in eradication of MRSA from the nares of cotton rats. This justifies further development of epidermicin for this indication.

dc.format.extentdkw457-dkw457
dc.format.mediumPrint
dc.languageen
dc.language.isoen
dc.publisherOxford University Press (OUP)
dc.relation.replaceshttp://hdl.handle.net/10026.1/8588
dc.relation.replaces10026.1/8588
dc.subjectAdministration, Topical
dc.subjectAnimals
dc.subjectAntimicrobial Cationic Peptides
dc.subjectBacterial Load
dc.subjectBacteriocins
dc.subjectDose-Response Relationship, Drug
dc.subjectMethicillin-Resistant Staphylococcus aureus
dc.subjectMupirocin
dc.subjectNose
dc.subjectRats
dc.subjectSigmodontinae
dc.subjectStaphylococcal Infections
dc.titleA single dose of epidermicin NI01 is sufficient to eradicate MRSA from the nares of cotton rats
dc.typejournal-article
dc.typeJournal Article
dc.typeResearch Support, Non-U.S. Gov't
plymouth.author-urlhttps://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000398038800017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008
plymouth.issue3
plymouth.volume72
plymouth.publication-statusPublished online
plymouth.journalJournal of Antimicrobial Chemotherapy
dc.identifier.doi10.1093/jac/dkw457
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/School of Biomedical Sciences
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR
plymouth.organisational-group/Plymouth/Research Groups/Plymouth Institute of Health and Care Research (PIHR)
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
plymouth.organisational-group/Plymouth/Users by role/Researchers in ResearchFish submission
dc.publisher.placeEngland
dcterms.dateAccepted2016-09-29
dc.identifier.eissn1460-2091
dc.rights.embargoperiodNot known
rioxxterms.funderBiotechnology and Biological Sciences Research Council
rioxxterms.identifier.projectDevelopment of epidermicin NI01 for nasal decolonization
rioxxterms.versionofrecord10.1093/jac/dkw457
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2016-12-13
rioxxterms.typeJournal Article/Review
plymouth.funderDevelopment of epidermicin NI01 for nasal decolonization::Biotechnology and Biological Sciences Research Council
plymouth.oa-locationhttps://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dkw457


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV